Related Experiment Video

Updated: Jun 26, 2025

Mimicking the Function of Signaling Proteins: Toward Artificial Signal Transduction Therapy
12:24

Mimicking the Function of Signaling Proteins: Toward Artificial Signal Transduction Therapy

Published on: September 29, 2016

7.0K

Potential of targeting signal-transducing adaptor protein-2 in cancer therapeutic applications

Taiga Maemoto1, Yuto Sasaki1, Fumiya Okuyama1

  • 1Department of Immunology, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo 060-0812, Japan.

Exploration of Targeted Anti-Tumor Therapy
|May 15, 2024
PubMed

Insights

A novel peptide inhibitor targeting Signal-Transducing Adaptor Protein-2 (STAP-2) interactions with BRK and EGFR shows promise for treating prostate and lung cancers by suppressing tumor growth.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Drug Discovery

Background:

  • Adaptor proteins regulate intracellular signaling pathways.
  • Signal-transducing adaptor protein-2 (STAP-2) interacts with breast tumor kinase (BRK) and epidermal growth factor receptor (EGFR).
  • STAP-2/BRK dysregulation is implicated in breast cancer, while STAP-2 stabilizes EGFR in prostate cancer, driving proliferation.

Purpose of the Study:

  • To investigate the therapeutic potential of inhibiting STAP-2 interactions with BRK and EGFR.
  • To evaluate a peptide inhibitor designed to disrupt STAP-2/BRK/EGFR binding.
  • To assess the efficacy of the peptide inhibitor in preclinical cancer models.

Main Methods:

  • Utilized molecular biology techniques to study STAP-2 interactions.
  • Developed and tested a peptide inhibitor targeting STAP-2 binding domains.
  • Evaluated the inhibitor's effects on protein interactions, cancer cell proliferation, and tumor formation in xenograft models.

Main Results:

  • The peptide inhibitor successfully blocked STAP-2/EGFR interaction and EGFR stabilization.
  • Inhibition of STAP-2/EGFR signaling suppressed cancer cell growth.
  • The peptide inhibitor demonstrated efficacy in reducing tumor formation in prostate and lung cancer xenograft models.

Conclusions:

  • Inhibiting STAP-2/BRK/EGFR interactions represents a viable therapeutic strategy for cancers.
  • The identified peptide inhibitor is a promising candidate for treating prostate and lung cancers.
  • Further development of STAP-2-targeting peptides may offer novel cancer treatment options.
Keywords:
Signal-transducing adaptor proteinepidermal growth factor receptorlung cancerpeptidesprostate cancersignal transduction

More Related Videos

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.2K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

493

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
518
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K